Oliver Engert Purchases 1,000 Shares of Enovis (NYSE:ENOV) Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert purchased 1,000 shares of Enovis stock in a transaction on Monday, June 1st. The stock was purchased at an average price of $22.22 per share, for a total transaction of $22,220.00. Following the completion of the transaction, the insider owned 49,640 shares of the company’s stock, valued at approximately $1,103,000.80. This represents a 2.06% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Oliver Engert also recently made the following trade(s):

• On Friday, March 13th, Oliver Engert purchased 1,000 shares of Enovis stock. The stock was purchased at an average price of $23.74 per share, for a total transaction of $23,740.00.
• On Monday, March 9th, Oliver Engert purchased 1,000 shares of Enovis stock. The stock was purchased at an average price of $23.39 per share, for a total transaction of $23,390.00.
• On Friday, March 6th, Oliver Engert purchased 750 shares of Enovis stock. The stock was purchased at an average price of $24.41 per share, for a total transaction of $18,307.50.

Enovis Price Performance

NYSE:ENOV opened at $22.86 on Friday. The firm has a market cap of $1.32 billion, a PE ratio of -1.15 and a beta of 1.38. Enovis Corporation has a 12 month low of $20.82 and a 12 month high of $36.82. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87. The company’s 50-day moving average price is $24.02 and its two-hundred day moving average price is $24.80.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. The firm had revenue of $589.15 million for the quarter, compared to analyst estimates of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts anticipate that Enovis Corporation will post 3.65 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on ENOV shares. William Blair started coverage on shares of Enovis in a research note on Friday, April 17th. They issued an “outperform” rating for the company. Evercore reaffirmed an “outperform” rating and issued a $36.00 target price on shares of Enovis in a research note on Friday, May 8th. BTIG Research reaffirmed a “buy” rating and issued a $39.00 target price on shares of Enovis in a research note on Friday, May 22nd. Wells Fargo & Company dropped their target price on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Finally, Needham & Company LLC boosted their target price on shares of Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.50.

Hedge Funds Weigh In On Enovis

A number of institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC raised its stake in shares of Enovis by 11.6% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 757,673 shares of the company’s stock worth $20,086,000 after buying an additional 78,497 shares during the last quarter. Impax Asset Management Group plc raised its stake in shares of Enovis by 47.5% during the third quarter. Impax Asset Management Group plc now owns 310,630 shares of the company’s stock worth $9,425,000 after buying an additional 100,000 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Enovis by 2.0% during the third quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company’s stock worth $197,945,000 after buying an additional 125,460 shares during the last quarter. Deroy & Devereaux Private Investment Counsel Inc. bought a new stake in shares of Enovis during the fourth quarter worth approximately $2,929,000. Finally, Public Sector Pension Investment Board raised its stake in shares of Enovis by 14.5% during the third quarter. Public Sector Pension Investment Board now owns 222,939 shares of the company’s stock worth $6,764,000 after buying an additional 28,236 shares during the last quarter. 98.45% of the stock is owned by institutional investors.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.